We believe in the power of collaboration to drive innovation in drug discovery. We are actively seeking partnerships with pharmaceutical and biotech companies that share our vision of using artificial intelligence to accelerate the identification of promising drug candidates.
By partnering with us, you will gain access to our AI-powered virtual screening platform, AíChemy. With its cutting-edge algorithms and massive compound database, AíChemy can quickly and efficiently identify potential drug candidates with a high probability of success. Our platform is customizable to your specific needs, and our team of experts is on hand to provide technical support and guidance throughout the drug discovery process.
Why Choose Us
Partnering with us offers numerous benefits, including:
Accelerated drug discovery
By leveraging the power of Scientific AI, our virtual screening platform can rapidly identify the most promising drug candidates, saving time and resources.
Increased success rates
AíChemy's Scientific AI models and extensive compound database can identify drug candidates with a higher probability of success, increasing the chances of developing a successful drug.
Our SaaS platform offers an affordable solution for virtual screening, without the need for expensive hardware or software.
Our platform can be tailored to your specific research needs, providing flexibility and customization.
Long term collaborations
We are committed to fostering long-term, collaborative relationships with our partners, and are dedicated to providing the highest level of service and support. If you are interested in partnering with us to accelerate your drug discovery efforts, please contact us to learn more about our platform and discuss potential collaboration opportunities.
We are proud to have Red Glead Discovery as our valued partner in our mission to revolutionize drug discovery through the power of artificial intelligence. Red Glead Discovery is a leading provider of integrated drug discovery services, offering a range of expertise from medicinal chemistry and synthesis to ADME and biology, supported by computational chemistry as well as advanced MS and NMR analysis.
Red Glead Discovery's project management skills and cross-disciplinary capabilities make them a preferred partner for clients and partners that want to develop compounds with high potential to become successful drugs. Their expertise in fragment-based drug discovery, including access to their proprietary technique Weak Affinity Chromatography (WAC), complements our AI-powered virtual screening platform.
Together, we were awarded a Eurostars R&D grant to deliver an AI-based tool for drug discovery, leveraging Desupervised's Bayesian deep learning models and Red Glead Discovery's expert knowledge in small molecule drug discovery. Our collaboration aims to introduce an entirely new product to the market, empowering our clients to innovate at greater speed utilizing AI and machine learning.
We are excited to continue our partnership with Red Glead Discovery as we work together to accelerate drug discovery and bring novel therapeutics to patients in need. Visit their website or contact them directly to learn more about their integrated drug discovery services.
“The collaboration with Desupervised fits perfectly with our strategy to become a leading and sustainable European drug discovery company. While RGD’s service platform increasingly attracts international biotech and large, global pharmaceutical companies, we are keen to extend and improve our service offer with AI technology. ”